Receive our newsletter – data, insights and analysis delivered to you
June 28, 2009

Takeda’s New Diabetes Drug Fails to Gain US Approval

Takeda Pharmaceutical has failed to gain regulatory approval from the US Food and Drug Administration (FDA) to market its new once-daily diabetes treatment alogliptin. The FDA rejected the drug based on insufficient data and requested more information on the cardiovascular risks associa

By cms admin

Takeda Pharmaceutical has failed to gain regulatory approval from the US Food and Drug Administration (FDA) to market its new once-daily diabetes treatment alogliptin.

The FDA rejected the drug based on insufficient data and requested more information on the cardiovascular risks associated.

The decision provides a major setback to Takeda, which planned to market alogliptin as a successor to the diabetes drug Actos, set to lose patent protection in 2011.

Resubmitting the application is expected to take up to two years.

Takeda had been informed in March 2009 that there was insufficient clinical data on alogliptin based on new guidelines on diabetes treatments and cardiovascular risks released by the FDA in December 2008.

Takeda shares fell 1.6% on 29 June after the rejected application had been announced.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU